Abstract
Acute myeloid leukemia is a heterogeneous group of diseases accounting for 15-20% of all tumors diagnosed in children under 15 years of age. The past few decades have yielded remarkable improvements in long-term outcomes for children with acute myeloid leukemia. A better risk-group stratification of patients based upon clinical and biologic features, a more effective use of anti-leukemic agents and enormous improvements in supportive care have increased the probability of cure by approximately 60%. The increase in our understanding of the biology of this disease has resulted in the development of molecularly targeted therapies that are potentially more effective and less toxic than the standard approaches. We here review novel molecularly targeted drugs for the treatment of childhood acute myeloid leukemia such as monoclonal antibodies, inhibitors of signalling molecules, proteasome inhibitors and epigenetic agents. For these recently patented agents, we also provide a detailed analysis of the published preclinical data and the clinical trials that have been completed.
Keywords: Pediatric acute myeloid leukemia, monoclonal antibodies, FMS-Like tyrosin kinase 3 (FLT3) inhibitors, DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, farnesyltransferase Inhibitor, mammalian target, rapamycin (mTOR) inhibitors, epigenetic agents
Recent Patents on Anti-Cancer Drug Discovery
Title: Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Volume: 6 Issue: 3
Author(s): Riccardo Masetti, Katharina Kleinschmidt, Carlotta Biagi and Andrea Pession
Affiliation:
Keywords: Pediatric acute myeloid leukemia, monoclonal antibodies, FMS-Like tyrosin kinase 3 (FLT3) inhibitors, DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, farnesyltransferase Inhibitor, mammalian target, rapamycin (mTOR) inhibitors, epigenetic agents
Abstract: Acute myeloid leukemia is a heterogeneous group of diseases accounting for 15-20% of all tumors diagnosed in children under 15 years of age. The past few decades have yielded remarkable improvements in long-term outcomes for children with acute myeloid leukemia. A better risk-group stratification of patients based upon clinical and biologic features, a more effective use of anti-leukemic agents and enormous improvements in supportive care have increased the probability of cure by approximately 60%. The increase in our understanding of the biology of this disease has resulted in the development of molecularly targeted therapies that are potentially more effective and less toxic than the standard approaches. We here review novel molecularly targeted drugs for the treatment of childhood acute myeloid leukemia such as monoclonal antibodies, inhibitors of signalling molecules, proteasome inhibitors and epigenetic agents. For these recently patented agents, we also provide a detailed analysis of the published preclinical data and the clinical trials that have been completed.
Export Options
About this article
Cite this article as:
Masetti Riccardo, Kleinschmidt Katharina, Biagi Carlotta and Pession Andrea, Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957775
DOI https://dx.doi.org/10.2174/157489211796957775 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription
Current Molecular Pharmacology Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)